+71.4%
XLC vs MRNA
+34.8%
+36.6%
-18.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | +5.4% | -4.4% | +0.9% |
| 7D | +0.5% | -1.1% | +1.6% | +0.5% |
| 30D | +2.1% | +126.1% | -124.0% | -1.0% |
| 3M | +0.7% | +190.0% | -189.3% | -4.1% |
| 6M | -3.2% | +157.2% | -160.4% | -7.3% |
| YTD | -3.8% | +388.2% | -392.0% | -11.8% |
| 1Y | -2.0% | +467.0% | -469.1% | -11.4% |
| 3Y | +71.4% | +36.1% | +35.3% | +59.4% |
| All | +71.4% | +34.8% | +36.6% | +59.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling